Hong Kong Consensus Recommendations on the Management of Hepatocellular Carcinoma

Ronnie Tung-Ping Poona Tom Tan-To Cheunga Philip Chong-Hei Kwokb Ann-Shing Lee c Tat-Wing Líd Kwok-Loon Loke e Stephen Lam Chan f Moon-Tong Cheungg Tak-Wing Lai h Chin-Cheung Cheung i Foon-Yiu Cheung j Ching-Kong Loo k Yiu-Kuen But l Shing-Jih Hsu l Simon Chun-Ho Yum m Thomas Yau l

aDepartment of Surgery, The University of Hong Kong, Queen Mary Hospital, bDepartment of Radiology and Imaging, Queen Elizabeth Hospital, cDepartment of Clinical Oncology, Tuen Mun Hospital, dDepartment of Medicine, Pamela Youde Nethersole Eastern Hospital, eDepartment of Radiology and Organ Imaging, United Christian Hospital, fDepartment of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, gDepartment of Surgery, Queen Elizabeth Hospital, hDepartment of Surgery, Princess Margaret Hospital, iDepartment of Surgery, Tuen Mun Hospital, jDepartment of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, kDepartment of Medicine and Geriatrics, Kwong Wah Hospital, lDepartment of Medicine, The University of Hong Kong, Queen Mary Hospital, mDepartment of Imaging and Interventional Radiology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, SAR (China)

Key Words
Consensus · Hepatocellular carcinoma · Hong Kong

Abstract
Background: Hepatocellular carcinoma (HCC) is particularly prevalent in Hong Kong because of the high prevalence of chronic hepatitis B (CHB) infection; HCC is the fourth commonest cancer in men and the seventh commonest in women, and it is the third leading cause of cancer death in Hong Kong. The full spectrum of treatment modalities for HCC is available locally; however, there is currently no local consensus document detailing how these modalities should be used. Summary: In a series of meetings held between May and October 2013, a multidisciplinary group of Hong Kong clinicians – liver surgeons, medical oncologists, clinical oncologists, hepatologists, and interventional radiologists – convened to formulate
local recommendations on HCC management. These recommendations consolidate the most current evidence pertaining to HCC treatment modalities, together with the latest thinking of practicing clinicians engaged in HCC management, and give detailed guidance on how to deploy these modalities effectively for patients in various disease stages. **Key messages:** Distinct from other regional guidelines, these recommendations provide guidance on the use of antiviral therapy to reduce the incidence of HCC in CHB patients with cirrhosis and to reduce recurrence of CHB-related HCC.

The sixth most common cancer worldwide [1], hepatocellular carcinoma (HCC) is particularly prevalent in Hong Kong because of the high prevalence of chronic hepatitis B (CHB) infection – it is the fourth commonest cancer in men and the seventh commonest in women, and it is the third leading cause of cancer death in Hong Kong [2].

The full spectrum of treatment modalities for HCC is available locally, including surgical resection, liver transplantation, local ablation, transcatheter arterial chemoembolization (TACE), transcatheter arterial radioembolization (TARE), external radiotherapy, and the multikinase inhibitor sorafenib. However, there is currently no local consensus document detailing how these modalities should be used. The Barcelona Clinic Liver Cancer (BCLC) staging system [3] – widely accepted in clinical practice in Western countries – does not recognize the evolving role of a number of modalities in various disease stages [4], and so is viewed as inadequate for use in Asia. The consensus recommendations developed by the Asian Pacific Association for the Study of the Liver (APASL) [5] more closely reflect local clinical practice, but even these are unable to provide nuanced guidance on specific scenarios encountered by Hong Kong clinicians treating HCC. Very recently, Yau et al. published the Hong Kong Liver Cancer (HKLC) staging system, a prognostic classification scheme with treatment guidance for Asian patients with HCC [6]. However, while the staging system provides a treatment algorithm together with the classification scheme, they do not expound on specific treatment strategies.

There is a need for treatment recommendations that take into account local circumstances, and which span indications and specific techniques, to ensure optimum patient outcomes.

**Methods**

In a series of three meetings held between May and October 2013, a multidisciplinary group of Hong Kong clinicians – liver surgeons (n=5), medical oncologists (n=2), clinical oncologists (n=2), hepatologists (n=4) and interventional radiologists (n=3) – convened to formulate recommendations on HCC management. Local clinicians known to have a special clinical and/or research interest in HCC management were invited from the two universities and eight main public hospitals of Hong Kong to form a panel that was broadly representative in terms of institutions and specialties.

Consensus statements were developed by designated group members prior to the meetings; statements were circulated among the members and modified according to feedback. At the meetings, each statement was assessed on a five-point Likert scale (1. Accept completely, 2. Accept with some reservations, 3. Accept with major reservations, 4. Reject with reservations, 5. Reject completely); voting was done via electronic keypads to encourage independent assessment. Agreement by 80% of the group to accept completely a statement was defined as consensus on that statement. A statement for which consensus was not achieved was modified, after which it was voted upon until consensus was reached. Many of the statements were developed with reference to other regional consensus guidelines, including those of the APASL [5] and of the Japan Society of Hepatology (JSH) [7], with modifications based on local practice. Finally, the group evaluated each statement’s level of evidence as per the 2011 Oxford criteria [8]. Where applicable, the levels are given in parentheses at the end of the recommendations.
Consensus Recommendations

Surgical Resection

1. Liver resection is generally a first-line curative treatment for solitary or multifocal HCC confined to the liver, anatomically resectable, and with satisfactory liver function reserve [5]. (Level 4)

2. In Child-Pugh A/B patients with ≤3 tumors measuring ≤2 cm in diameter, without extrahepatic lesions or vascular invasion, either resection or ablation may be conducted. (Level 4)

   Resection is the mainstay curative treatment for small tumors, although ablation is often considered a viable alternative in the local setting. Location of the lesion is important: for centrally located tumors, the common practice in Hong Kong is to perform ablation in lieu of resection in an effort to preserve liver function. Resection of multinodular HCC is associated with reasonable long-term survival outcomes [9]. For tumors >2 cm in diameter, resection is preferred to ablation.

3. Resection may be considered in patients with intrahepatic portal vein or hepatic vein branch invasion; the presence of main portal vein or inferior vena cava tumor thrombosis is generally a contraindication for resection [5]. (Level 4)

   An aggressive surgical strategy targeting patients with tumor thrombosis limited to the intrahepatic portal branches can result in significant survival benefit [10, 11]. This is corroborated by results from the performance assessment of the HKLC staging system, which demonstrated the survival benefit of radical curative therapies, including resection, for BCLC-B and BCLC-C patients classified as HKLC-II – a subset which includes patients with small tumors with intrahepatic vascular invasion [6].

4. Resection of isolated extrahepatic metastasis after hepatic resection is justified in selected patients. (Level 4)

   There is an expanding body of evidence indicating favorable survival outcomes in selected HCC patients after resection of pulmonary or abdominal metastases [12–15].

5. Patients with a predominant large mass in one lobe and one or two small tumor nodules in the other lobe may benefit from combined resection of the predominant tumor and resection or ablation of the contralateral nodules [5]. (Level 4)

   Recent studies have shown that combined hepatectomy and radiofrequency ablation (RFA) is a safe, effective treatment for selected patients with multifocal HCC [16–18]. Of note, in Hong Kong, some clinicians may elect to perform TACE first-line, followed by combined resection-ablation if there is good response to therapy, even in the absence of published data.

6. In HCC patients with borderline liver function and liver remnant volume for major hepatectomy, preoperative portal vein embolization to induce hypertrophy of liver remnant can reduce the chance of liver failure. (Level 1)

   A meta-analysis of 37 studies, involving a total of 1,088 patients, concluded that preoperative portal vein embolization is safe and effective in inducing liver hypertrophy to prevent post-resection liver failure resulting from insufficient liver remnant [19].

7. Laparoscopic hepatectomy in selected patients is associated with long-term outcomes similar to open hepatectomy, with fewer operative complications and shorter hospital stays. (Level 4)

   There have been no randomized controlled trials (RCTs) to date comparing open and laparoscopic hepatectomy for HCC. However, numerous matched case-control studies have reported similar survival rates comparing these modalities [20–23]. The likelihood of a favorable outcome is increased when the laparoscopic procedure is performed on properly selected patients by an experienced surgical team [21].

8. The anterior approach is the preferred approach for large, right-lobe HCC. (Level 2)
Results of a 2006 RCT showed that the anterior approach was associated with less operative blood loss and significantly longer overall survival (OS) compared with the conventional approach for large right liver tumors [24]. A more recent retrospective review reported a lower recurrence rate and longer disease-free survival (DFS) with the anterior approach, although an OS benefit was not demonstrated [25].

There is, as yet, no well-proven effective adjuvant treatment to prevent recurrence of HCC after curative-intent resection [5]. (Level 2)

Aggressive treatment of intrahepatic tumor recurrence with surgical or locoregional therapy can prolong patient survival [5]. (Level 4)

In selected patients with recurrent HCC within transplant criteria, salvage liver transplantation can be considered when repeated hepatic resection or ablation is not feasible. (Level 3)

Several approaches, including adjuvant interferon [26] and adoptive immunotherapy [27], have been reported to reduce HCC recurrence rates in small-sample RCTs, but their potential benefits have not been validated by subsequent studies. A recently completed trial of adjuvant sorafenib after surgical resection or local ablation did not meet its primary endpoint of improving recurrence-free survival [28]. To date, there have been no RCTs comparing survival outcomes of the various surgical and locoregional modalities in the treatment of recurrent HCC. Similar survival outcomes have been reported for repeated resection and RFA, although the greater repeatability of RFA, and that it can be delivered percutaneously, makes it an attractive option for selected patients [29]. Of note, a recently published retrospective analysis of data from a single center showed that salvage transplantation and repeated resection led to comparable survival outcomes, and that both treatments resulted in significantly better survival outcomes than repeated RFA [30]. In Hong Kong, it is the usual practice to attempt surgical resection to treat a first recurrence then perform RFA or TACE for subsequent recurrences.

Liver Transplantation

For patients aged ≤65 years with Child-Pugh C cirrhosis, liver transplantation provides the best curative treatment of early HCC within transplant criteria [5, 7]. (Level 4)

Transplantation can be considered for Child-Pugh A/B patients with unresectable HCC who meet transplant criteria. (Level 4)

In centers where graft shortage is a severe problem, resection or ablation as first-line treatment for Child-Pugh A patients, followed by salvage transplantation for recurrent tumors or liver failure, is a reasonable strategy [5]. (Level 4)

We adopted the position of the APASL and the JSH on orthotopic liver transplantation being the ideal first-line treatment for Child-Pugh C patients meeting the Milan criteria. The main barrier to implementation of this recommendation is donor availability – as in the rest of the region, there is a severe shortage of grafts in Hong Kong.

Liver transplantation for patients with small HCC and compensated cirrhosis remains controversial. While advocates point to the excellent disease-free survival outcomes associated with transplantation in this group [31, 32], critics argue that resection should be first-line instead, given that OS results of the two modalities are largely similar and that adding these patients to the transplant recipient pool will lengthen transplant waiting times, compounding the existing graft shortage. In Hong Kong, transplantation is occasionally considered for Child-Pugh A/B patients meeting the Milan criteria.

The University of California, San Francisco (UCSF) criteria may be used as an alternative to the Milan criteria, with acceptable long-term survival results; the survival benefits associated with other expanded criteria have yet to be validated. (Level 4)
Hong Kong transplant surgeons utilize the UCSF criteria, which expand the indication of transplantation to solitary tumors ≤6.5 cm, or three or fewer nodules with the largest lesion ≤4.5 cm and a total tumor diameter of ≤8.0 cm [33]. A growing number of cohort studies have shown that survival outcomes of transplant patients chosen under the UCSF criteria are comparable to that for Milan-qualified patients [34–36]. Other groups have proposed their own versions of expanded criteria [37–41], but the survival outcomes reported for patients chosen under these have yet to be validated in larger cohorts.

16. Living-donor liver transplantation is an acceptable option for HCC within transplant criteria when deceased-donor graft is not available, but the potential risk of donor mortality and complications need to be considered in offering such treatment [5]. (Level 1)

A 2012 meta-analysis covering seven studies and 1,310 patients [42], and a Canadian cohort study of 345 patients [43], found no differences in OS and recurrence rates between living-donor and deceased-donor transplantation. That there exists a small chance of donor mortality from complications of surgery [44], as well as the likelihood of recipient complications [45], mandates rigorous post-procedure follow-up of both recipients and donors of living-donor transplantation.

17. Bridge therapy using chemoembolization or local ablation may reduce dropout due to tumor progression with long waiting times of >6 months [5], but there is no proven benefit in long-term survival. (Level 4)

Bridge therapy refers to pre-transplant resection, local ablation or TACE to prevent tumor progression while the patient waits for transplantation. Importantly, tumor progression during this waiting period may be associated with vascular invasion, a strong determinant of postoperative recurrence [46]. The benefit of TACE is seen largely with mean waiting time in the transplant list of >6 months [47]. There is currently no evidence that bridge therapy in patients transplanted within 6 months of being listed reduces the risk of tumor progression or improves survival after transplantation.

18. The role of liver transplantation for HCC initially beyond transplant criteria downstaged to within criteria after locoregional therapy is still controversial. (Level 1)

Downstaging refers to reducing the size of a tumor via resection, local ablation or TACE, specifically to meet the criteria for transplantation [48]. A recent systematic review reported that downstaging is feasible in up to 69% of patients, with OS and DFS rates comparable to those in patients within transplant criteria [49]. Nonetheless, given the severe shortage of grafts in Hong Kong, we agreed that priority for transplantation should be given to patients within transplant criteria, whose chances for a good survival outcome are likely to be high. Adding downstaged patients to the transplant recipient pool will lengthen transplant waiting times, compounding the existing graft shortage.

Local Ablation

19. Local ablation is an acceptable alternative to resection for small HCC (<2 cm) in Child-Pugh A/B patients [5]. (Level 4)

20. Local ablation is the treatment of choice for unresectable, solitary HCC <5 cm or 2–3 nodules <3 cm in Child-Pugh A/B patients when transplantation is not feasible. (Level 4)

Image-guided percutaneous ablation therapies are frequently utilized in Hong Kong, with RFA the most widely used technique. It is generally accepted that local ablation is for patients with small HCC (<5 cm) confined to the liver that is unresectable due to limited liver reserve or compromised liver function [50]. Tumor size is a risk factor for both local recurrence [51, 52] and incomplete ablation [53]. A local study reported technical feasibility of complete ablation for tumors up to 8 cm in diameter [54], but the long-term survival benefit of RFA for such large tumors has yet to be established.
21. For HCC nodules 3–5 cm in diameter, the combination of TACE and ablation may be more beneficial than ablation alone. (Level 1)

22. For >3 nodules, ablation combined with TACE may be beneficial in selected patients. (Level 4)

23. For solitary tumors 5–7 cm in diameter, ablation combined with TACE may be beneficial in selected patients. (Level 2)

A recently published meta-analysis of seven RCTs reported that RFA plus TACE significantly improved survival rates at 1, 3 and 5 years compared with RFA alone in patients with tumors >3 cm, but not in patients with tumors <3 cm [55]. Moreover, there is emerging evidence that the ablation-TACE combination provides a survival benefit over ablation alone in patients with multiple tumors [56] and in those with larger solitary tumors up to 7 cm [56, 57].

24. For resectable tumors 2–5 cm in diameter, whether RFA can replace resection as the treatment of choice remains controversial. (Level 1)

Surgical resection is associated with greater OS and DFS rates than RFA, according to the results of a 2013 systematic review and meta-analysis covering two RCTs and 10 non-RCTs; however, ablation is associated with fewer post-treatment complications and shorter hospital stays [58]. Conversely, there are data from other RCTs showing comparable long-term survival outcomes with resection and RFA [59, 60].

25. RFA via the surgical approach is preferred when tumor location incurs a high risk of biliary or visceral injury by the percutaneous approach, and may offer a survival benefit for patients with large HCC >3 cm. (Level 4)

The incidence of postoperative complications and local tumor progression is lower after surgical than after percutaneous ablation [61]. While complete ablation rates are similar when performing the percutaneous approach versus the surgical approach for medium-sized HCC (3.1–5 cm), 1- and 3-year survival rates are significantly higher in patients managed via the surgical approach [62].

26. RFA is superior to ethanol injection in the treatment of small HCCs in terms of treatment response, recurrence, and OS [5]. (Level 1)

Percutaneous ethanol injection still has a role in small HCC <2 cm not suitable for thermal ablation. (Level 5)

Statement 26 is based on the results of a meta-analysis of five RCTs [63]. Nonetheless, not all lesions are suitable for RFA (e.g., tumors near the biliary tree); for these, percutaneous ethanol injection may be reasonably attempted.

28. Microwave ablation is a safe and effective modality for treatment of HCC. It is an alternative option to RFA. (Level 4)

29. Microwave ablation may be more effective than RFA for tumors adjacent to big vessels owing to less heat-sink effect; more clinical studies are needed to confirm this benefit. (Level 4)

In some Asian centers, microwave ablation is utilized as an alternative to RFA, with several studies reporting similar survival outcomes [64–67]. The heat-sink effect is defined as tissue cooling by adjacent visible vessels that causes deflection of the ablation zone away from the vessel [68]; this protective effect of blood flow in the liver may help explain the high rate of local recurrence seen in some clinical series of RFA [69]. In animal models, pathological examination of lesions that had been subjected to microwave ablation showed significantly less blood vessel-mediated cooling than lesions post-RFA [69, 70], suggesting that microwave ablation may lead to fewer tumor recurrences in the long term. However, prospective studies comparing microwave ablation to RFA are needed to show its clinical benefit for tumors close to major vessels.
30. High-intensity focused ultrasound (HIFU) ablation is safe and effective in the treatment of small HCCs. It can achieve survival outcomes comparable to those of RFA and thus serves as a good alternative treatment for patients with cirrhosis. (Level 4)

31. HIFU ablation is generally well tolerated in HCC patients with Child-Pugh A/B cirrhosis. It may have some advantage in selected patients, such as those with ascites or with tumors close to major bile ducts. (Level 4)

32. HIFU may be used as an alternative bridging therapy for HCC patients awaiting liver transplantation. (Level 4)

HIFU is now in use at one Hong Kong center [71], where similar survival outcomes compared with RFA for patients with HCC <3 cm [72] and for those with recurrent HCC [73] have been observed. HIFU can be performed safely in patients with gross ascites, which both serves as a medium for energy transfer and protects subcutaneous tissue from being damaged by the focused ultrasound energy [74]. Finally, data from a retrospective study showed that significantly more HIFU-bridged patients had a complete response to treatment compared with TACE-treated patients [75].

33. Irreversible electroporation should be considered an investigational modality in HCC. (Level 4)

We reviewed the promising data from preliminary studies of irreversible electroporation [76–78], but agreed that they are insufficient to develop a recommendation for (or against) its use in Hong Kong.

**Transarterial Chemoembolization**

34. TACE is recommended as a first-line treatment for patients with unresectable, large/multifocal HCCs, with no vascular invasion or extrahepatic spread, and with satisfactory liver function (Child-Pugh A/B) [5]. (Level 1)

35. Selective or superselective TACE should be attempted in order to preserve nontumorous liver parenchyma, maximize treatment effect, and minimize complications [5]. (Level 5)

36. Selective TACE can be performed in patients with small tumors in whom ablation is difficult to perform because of tumor location or medical comorbidities [5]. (Level 5)

TACE is the mainstay of therapy in Hong Kong for patients with large (>5 cm), unresectable HCC and Child-Pugh A/B cirrhosis, providing a significant survival benefit in this population [79–81]. That optimal TACE is premised on the highly selective embolization of tumor-feeding arteries makes it ideal even for small tumors, for which thermal ablative therapies are contraindicated.

37. TACE may offer survival benefit in HCC patients with minimal portal vein invasion [7]. (Level 1)

Portal vein thrombosis is generally considered a contraindication to TACE, but an ever increasing number of studies are reporting favorable survival outcomes with TACE in patients with minimal portal vein invasion [82–84]. Indeed, a recent meta-analysis of eight controlled trials reported survival benefits with TACE compared with conservative treatment in HCC patients with portal vein tumor thrombus, even in those with main portal vein obstruction; however, temporary liver decompensation and postembolization syndrome were noted to occur frequently [85].

38. TACE can be used as a bridge therapy for HCC patients awaiting transplantation. (Level 4)

There is evidence from small-sample, retrospective studies that bridge therapy with TACE is associated with good survival outcomes after liver transplantation [86, 87]. Furthermore, TACE may lower the HCC recurrence rate in patients meeting the Milan and UCSF criteria, and the response to TACE is likely a good indicator of low recurrence [88].
39. There is insufficient evidence to specify the most effective chemotherapeutic agent or combination regimen for TACE. (Level 1)

This was the conclusion of a 2007 systematic review of cohort and randomized studies of transarterial therapies [89]. Of note, cisplatin is the most widely used chemotherapeutic agent for conventional TACE procedures in Hong Kong, whereas doxorubicin is the preferred agent for TACE with drug-eluting beads (DEB).

40. TACE with DEB is a safe and effective treatment for HCC, but there is no clear evidence of survival benefit over lipiodol-based conventional TACE. (Level 1)

41. TACE-DEB may offer better tumor control in patients with advanced tumors, or in those who have failed conventional TACE. (Level 2)

The PRECISION V study randomized 212 patients with Child-Pugh A/B cirrhosis and large and/or multinodular, unresectable HCC to treatment with either TACE with doxorubicin-loaded beads or conventional TACE with doxorubicin [90]. Although TACE-DEB was associated with higher rates of complete response, objective response and disease control compared with conventional TACE, superiority was not demonstrated. A 2013 meta-analysis of seven studies concluded that the techniques yield comparable treatment response rates [91]. In PRECISION V, patients with Child-Pugh B cirrhosis, Eastern Cooperative Oncology Group (ECOG) 1 performance status, bilobar disease and recurrent disease displayed a significantly better response with TACE-DEB than with conventional TACE [90]; these findings validate the current practice of Hong Kong clinicians who reserve TACE-DEB for patients with more advanced tumors or for those in whom conventional TACE failed.

42. TACE should be repeated at intervals of 2–3 months based on assessment of tumor status and liver function. (Level 4)

In Hong Kong, the usual practice is to perform repeat-TACE when viable residual tumor or new tumor growth is observed in a patient with good liver function. Assessment of tumor status via computed tomography or magnetic resonance imaging is crucial: the efficacy and tolerability of TACE has been found to be greater when used only when tumor growth is detected [92]. Moreover, results of a recent retrospective study of 116 patients with unresectable HCC showed that, after a second chemoembolization procedure, up to 47% of initial TACE nonresponders showed a significant response [93]. Therefore, a reasonable approach would be to perform at least two TACE procedures on the same targeted lesion, after which further treatment with another modality should be considered if TACE fails.

43. TACE should be stopped when liver impairment develops or there are other serious complications. (Level 5)

44. TACE should be stopped when there is radiologic tumor progression (e.g., extrahepatic spread, development of vascular invasion, increase in tumor size) despite adequate drug administration. (Level 5)

45. For patients with post-TACE tumor progression confined to the liver, other locoregional therapies, such as Y-90 radioembolization, can be considered. Patients with extrahepatic spread should be treated with systemic therapy. (Level 5)

Currently, there is no consensus on what constitutes “TACE failure.” Raoul et al. proposed that no response after at least two sessions of TACE signifies TACE failure [94]. More recently, a panel of Asian experts defined TACE failure as no response after three or more TACE procedures to the same area within a 6-month period [95]. With statements 43 and 44, we specified two scenarios for which further TACE treatment is no longer warranted.

In general, TACE does not induce significant long-term worsening of liver function in patients with Child-Pugh A/B cirrhosis [96]; however, should hepatic decompensation occur after a TACE procedure, a repeat TACE is contraindicated because the ischemic damage associated with embolization can lead to a rapid decline in liver function and, potentially, death. Likewise, development of other serious post-TACE complications – including hepatic
artery injury, non-target embolization, liver abscess, and variceal bleeding [97] should preclude further TACE procedures. We agreed that radiologic progression after at least two TACE procedures warrants consideration of alternate therapy: TARE for patients with intrahepatic tumor progression, and sorafenib for patients with extrahepatic tumor spread.

46. Patients with liver-dominant tumor and limited extrahepatic spread may benefit from TACE. (Level 1)

Notwithstanding our recommendation of systemic therapy for patients with advanced HCC, there is growing evidence that this group may also derive benefit from TACE: a systematic review of 15 studies of TACE in HCC patients with vascular invasion or extrahepatic metastasis concluded that TACE can be safely performed in these patients [98]. Notably, four studies included in the review reported that TACE prolonged OS compared with conservative management, with patients with portal vein branch invasion and well-preserved liver function having more favorable survival outcomes. Of note, some Hong Kong clinicians will occasionally perform TACE in patients with small lymph node metastases or isolated lung metastasis, putting them at the leading edge of worldwide TACE practice.

**Transarterial Radioembolization**

47. TARE with yttrium-90-loaded resin/glass beads may be used as an alternative locoregional treatment for unresectable HCC. (Level 4)

48. TARE with yttrium-90 may offer benefit over TACE in HCC patients with large tumors, or tumors with portal vein invasion. (Level 4)

Three large-scale retrospective series have shown that TARE is a safe and effective treatment for patients with unresectable HCC [99–101]. International treatment guidelines acknowledge its role in the locoregional treatment of unresectable HCC [102, 103]. In Hong Kong, TARE is regarded mainly as an alternative to TACE, which is still preferred by most clinicians as the former requires substantially more time, cost and effort.

Whereas a compromised portal circulation is usually considered a contraindication to TACE, it is not considered a contraindication to radioembolization – the injected microspheres are unlikely to have a significant macroembolic effect that could lead to liver decompensation [104]. Regrettably, survival outcomes in radioembolized patients with main portal vein thrombosis have not been favorable (e.g., 3–6 months) [105, 106]. Patients with lobar or segmental portal vein thrombosis have fared better in studies, with median survival times of 10–14 months post-TARE [104, 105].

49. Lobar or segmental TARE can be used to induce lobar shrinkage and contralateral lobar hypertrophy, downstaging tumor for potential subsequent resection. (Level 4)

Subsequent resection after successful downstaging with TARE has been described in the literature [107, 108]; in selected patients, this approach provides the possibility of long-term survival [109]. Resection is usually carried out around 6–8 months after downstaging to allow time for the target tumor to shrink, the non-tumorous liver to hypertrophy, and remaining radiation to dissipate.

50. There is no evidence of clinical benefit of TARE over conventional TACE for patients with multinodular tumors without vascular invasion. (Level 4)

Retrospective analyses have shown that TARE and TACE result in similar survival and safety outcomes in patients with unresectable HCC [110, 111]. Very recently, however, the open-label, multicenter, pilot SIRTACE study showed that, after patients received a mean of 3.4 TACE interventions or one TARE treatment (yttrium-90 loaded resin microspheres), median progression-free survival (PFS) and OS were not significantly different between the two groups, suggesting that a single session of TARE may be as safe and effective as multiple TACE sessions; however, the study was not designed to measure differences in survival outcome [112]. Greater clarity on this issue will be derived from the results of the phase II, multicenter,
randomized, controlled TRACE trial, which will directly compare TACE-DEB with TARE (yttrium-90 loaded glass microspheres) [113].

**External Radiotherapy**

51. High-precision radiotherapy offers effective local control to selected HCC confined to the liver, with an acceptable toxicity profile in patients with Child-Pugh A cirrhosis. (Level 4)

52. High-precision radiotherapy is a viable option for unresectable HCC that is ineligible for or refractory to TACE or other locoregional therapies. (Level 4)

Recent advancements in radiotherapy technique now allow the delivery of a radiation dose that tightly conforms to tumor outline while sparing normal liver tissue [114]. High-dose, three-dimensional conformal radiotherapy (3-DCRT) has been shown to be well tolerated in the treatment of HCC patients with Child-Pugh A/B cirrhosis, with favorable response rates [115]. A local retrospective study of HCC patients treated with stereotactic radiotherapy showed a median survival of 23 months, and 1-year and 3-year OS rates of 62% and 28%, respectively [116]; similarly, a median survival of 17.2 months and a 1-year OS rate of 71.7% were reported by a local study assessing image-guided, highly-conformal radiotherapy [117].

In Hong Kong centers where TARE is not available, HCC patients have been shown to respond well to external radiotherapy. Results of a Korean series of 158 patients with unresectable HCC — including 51 patients undergoing salvage therapy after failure of repeated TACE — showed that external radiotherapy is associated with a median survival of 16 months, and 2-year and 5-year OS rates of 30.5% and 9%, respectively [118]. In a recently published Canadian prospective trial of stereotactic body radiation therapy (SBRT) in patients with predominately large, advanced-stage HCC not eligible for surgery, RFA or TACE, the authors reported a median OS of 17 months and a local control rate of 87% at 1 year [119].

53. High-precision radiotherapy may be combined with TACE for unresectable HCC, but the optimal sequencing and timing is not known, and the survival benefit is uncertain. (Level 4)

Patients with small, solitary, primary HCC treated with TACE followed by SBRT have been found to have greater complete response rates and longer DFS than patients treated with TACE alone [120]. Similarly, advanced HCC patients treated with TACE followed by 3-DCRT achieved favorable response rates and 1-, 3- and 5-year OS rates in a retrospective, non-comparative analysis [121]. A retrospective analysis of data from 412 registry patients concluded that the combination of TACE and 3-DCRT is a safe, effective option for relieving and/or stabilizing portal vein tumor thrombosis associated with advanced HCC [122]. More recently, Tang et al. retrospectively compared 3-DCRT followed by TACE versus surgical resection followed by TACE, and found that patients treated with the 3-DCRT-TACE combination had significantly greater OS rates than patients treated with the resection-TACE combination [123].

**Systemic Treatments**

54. Sorafenib is the first-line treatment for advanced-stage patients with Child-Pugh A cirrhosis who are not suitable for locoregional therapy [5]. (Level 2)

55. Sorafenib may possibly impart a survival benefit in selected patients with compensated Child-Pugh B cirrhosis. (Level 4)

In Hong Kong, sorafenib is the standard of care for patients with advanced HCC (i.e., extrahepatic spread or portal vein invasion) and Child-Pugh A cirrhosis. In two RCTs, sorafenib treatment was shown to prolong survival in patients with advanced disease which was not amenable to, or had progressed after, surgery or locoregional therapy [124, 125].

A retrospective analysis of data from 172 Hong Kong Chinese patients with advanced HCC treated with sorafenib showed similar clinical benefit rates and PFS comparing Child-
Pugh A patients and Child-Pugh B patients [126]. Conversely, PFS, time to progression (TTP) and OS were markedly longer in Child-Pugh A patients compared to Child-Pugh B patients in a prospective study of 300 Italian patients; nonetheless, the authors concluded that their data suggest that patients with Child-Pugh B cirrhosis may still benefit from sorafenib [127].

Importantly, worsening cirrhosis was associated with worsening outcomes – whereas Child-Pugh B patients with a cirrhosis score of 7 had a median OS similar to those with Child-Pugh A cirrhosis (5.4 versus 6.1 months), those with a score of 8 or 9 had a significantly less favorable survival outcome (2.3 months) in the local study [126]. Similar findings were observed in a retrospective study of 267 Korean patients [128].

In terms of safety, whereas the incidence of side effects was similar comparing Child-Pugh A patients and Child-Pugh B patients, Child-Pugh B patients developed more cirrhotic complications, including anemia, gastrointestinal bleeding and hepatic encephalopathy [126]. Therefore, the option for sorafenib treatment should be extended only to Child-Pugh B patients with "compensated cirrhosis," i.e., patients who have not developed cirrhotic complications; these patients should then be closely monitored for the development of such complications. The results of the global, non-interventional GIDEON study, aimed at evaluating the safety of sorafenib in all patients with unresectable HCC under real-life practice conditions, particularly for Child-Pugh B patients, are eagerly awaited [129].

56. Patients with extrahepatic tumor progression after locoregional therapy and with compensated liver function should be treated with sorafenib. (Level 2)

57. Sorafenib may also be used in patients with intrahepatic tumor progression after locoregional therapy and with compensated liver function. (Level 5)

A subanalysis of the pivotal SHARP trial showed that patients with macroscopic vascular invasion and/or extrahepatic spread treated with sorafenib had longer OS (8.9 versus 6.7 months) and TTP (4.1 versus 2.7 months) than patients treated with placebo; this is comparable to the outcomes in patients without macroscopic vascular invasion and/or extrahepatic spread, with those given sorafenib having an OS of 14.5 months versus 10.2 months for patients given placebo [130].

We recommend TARE (see statement 45) or external radiotherapy (see statement 52) for patients with intrahepatic tumor progression after TACE. However, given that sorafenib benefits patients with extrahepatic spread post-locoregional therapy, sorafenib may be a reasonable option even for those with intrahepatic spread.

58. There is evidence of safety for the combination of TACE and sorafenib in patients with intermediate/advanced-stage HCC; however, more evidence from phase III randomized clinical trials is needed to show survival benefit. (Level 2)

The phase II, single-arm, open-label START trial showed that conventional TACE followed by sorafenib is safe and effective, with no unexpected side effects [131]. The few RCTs that have been published have corroborated these safety findings but have not reported an OS benefit [132–134].

59. The combination of sorafenib and chemotheraphy may provide a survival benefit in selected patients with advanced HCC. (Level 2)

Data from a phase II, multinational RCT of 96 patients with advanced HCC and Child-Pugh A cirrhosis showed that treatment with sorafenib plus doxorubicin resulted in greater median TTP, OS and PFS compared with doxorubicin monotherapy [135]. More recently, Yau et al. reported the results of a phase II, multicenter, single-arm study evaluating the efficacy and tolerability of the combination of sorafenib, oxaliplatin and capecitabine (SECOX) in the treatment of 51 Asian patients with advanced HCC mostly from Hong Kong: median TTP was 5.29 months, median PFS was 5.26 months, and median OS was 11.73 months [136]. The authors concluded that their data support the conduct of an RCT comparing SECOX and sorafenib monotherapy in the treatment of advanced HCC.
Antiviral Therapy

60. Nucleoside/nucleotide analogue treatment may reduce the incidence of HCC in CHB patients with cirrhosis. (Level 4)

Recently published cohort studies support this approach; for instance, data from two studies showed that long-term treatment with the nucleoside analogue entecavir reduced the risk of HCC in patients with CHB [137, 138]. However, we noted that most trials examining this issue have been observational in nature. Furthermore, pooled data from 49 studies showed that HCC still developed at a rate of 1.3 per 100 patient years in CHB patients already receiving oral antiviral therapy [139], underscoring the need for continued HCC surveillance even in this treated population.

61. Nucleoside/nucleotide analogues have been shown to reduce recurrence and prolong survival after resection of hepatitis B virus (HBV)-related HCC and are recommended after curative hepatectomy. (Level 1)

62. Interferon-based antiviral treatment may reduce recurrence and prolong survival after complete removal or ablation of HCV-related HCC but is associated with significant side effects. (Level 1)

Results of a meta-analysis of nine studies, involving a total of 551 patients who had undergone either resection or ablation for HBV-related HCC, showed that post-treatment antiviral therapy was associated with a 41% reduction in risk of recurrence, as well as significant reductions in liver-related and overall mortality, compared with no therapy [140]. Antiviral therapy is particularly important for patients with a high viral load, for whom it is recommended before and/or after curative therapy of HCC [141].

Similarly, a meta-analysis of five studies, involving a total of 355 patients who had undergone curative treatment for HCV-related HCC, showed that interferon-alpha was associated with a 67% reduction in risk of recurrence, particularly in populations achieving high rates of sustained virologic response (SVR) [142]. However, interferon-alpha is associated with a wide spectrum of side effects (especially hematological toxicity) [143], the occurrence of which, especially in cirrhotic patients, can prevent reaching and maintaining the dose needed for maximal SVR. The use of new direct-acting antivirals for HCV is associated with SVR rates as high as 90% after only 12 weeks of treatment [144]; however, current data are insufficient to make a recommendation for their use in preventing HCC recurrence.

63. Anti-HBV therapy may reduce the risk of reactivation and liver failure in patients undergoing TACE and is recommended. (Level 4)

In a retrospective study examining 590 hepatitis B surface antigen-positive HCC patients who had undergone either surgical resection or TACE, the HBV-reactivation rate in the group of TACE-treated patients who had received anti-HBV therapy was 1.5% versus 17.5% in those who had not received anti-HBV therapy, and the rates of deterioration of liver function were 1.5% and 8.1%, respectively [145].

Conclusion

These recommendations consolidate the most current evidence pertaining to HCC treatment modalities, together with the latest thinking of practicing clinicians engaged in HCC management, resulting in detailed guidance on how to deploy these modalities effectively for patients in various disease stages.

Distinct from other guidelines, such as those developed by the European Association for the Study of the Liver [146] and the American Association for the Study of Liver Diseases [147, 148], these recommendations eschew traditionally imposed restrictions on the use of
certain modalities for specific stages only; emerging evidence from new studies, coupled with our experience of positive outcomes in our patients, is substantiating the benefit associated with the use of these modalities beyond the established indications (e.g., transplantation for Child-Pugh A/B patients with unresectable HCC who meet transplant criteria; TACE for patients with minimal portal vein invasion or extrahepatic spread). Moreover, the recommendations cover treatments not reviewed or endorsed by previous guidelines (e.g., HIFU for small HCCs; TARE for patients with unresectable HCC; the combination of sorafenib and chemotherapy for advanced HCC).

Notably, these recommendations provide guidance on the use of antiviral therapy to reduce the incidence of HCC in CHB patients with cirrhosis, and to reduce recurrence of CHB-related HCC.

Conflict of Interest

None declared.

Financial support: The meetings during which these consensus points were formulated and discussed were supported by an unrestricted educational grant from Bayer HealthCare Limited.

Acknowledgments

The authors would like to acknowledge Dr Jose Miguel (Awi) Curameng and Dr Horace Tsun-Bond Ho of MIMS (Hong Kong) Limited for providing editorial and writing support, which was funded by Bayer HealthCare Limited. The meetings during which these consensus points were formulated and discussed were supported by an unrestricted educational grant from Bayer HealthCare Limited.

References

1 World Cancer Research Fund International: Liver cancer. Available at: http://www.wcrf.org/cancer_statistics/data_specific_cancers/liver_cancer_statistics.php. Accessed 25 September 2013.
2 Hong KC: Top Ten Cancers in 2010. Available at: http://www3.ha.org.hk/cancereg/statistics.html. Accessed 25 September 2013.
3 Forner A, Reig ME, de Lope CR, Bruix J: Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010;30:61–74.
4 Burak KW, Kneteman NM: An evidence-based multidisciplinary approach to the management of hepatocellular carcinoma (HCC): the Alberta HCC algorithm. Can J Gastroenterol 2010;24:643–650.
5 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shina S, Cheng AL, Jia JD, Obi S, Han KH, Jafari W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK: Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439–474.
6 Yau T, Tang YV, Yao TJ, Fan ST, Lo CM, Poon RT: Development of Hong Kong Liver Cancer Staging System with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 2014;146:1691–1700.e3.
7 Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M, HCC Expert Panel of Japan Society of Hepatology: Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011;29:339–364.
8 OCEBM Levels of Evidence Working Group: The Oxford 2011 Levels of Evidence. Available at: http://www.cebm.net/mod_product/design/files/CEBM-Levels-of-Evidence-2.1.pdf. Accessed 25 September 2013.
9 Ng KK, Vauthey JN, Pawlik TM, Lauwers GY, Regimbeau JM, Belghiti J, Ikai I, Yamaoka Y, Curley SA, Nagorney DM, Ng IO, Fan ST, Poon RT, International Cooperative Study Group on Hepatocellular Carcinoma: Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol 2005;12:364–373.
10 Le Treut YP, Hardwigsen J, Ananian P, Saisse J, Grégoire E, Richa H, Campan P: Resection of hepatocellular carcinoma with tumor thrombus in the major vasculature. A European case-control series. J Gastrointest Surg 2006;10:855–862.

11 Shi J, Lai EC, Li N, Guo WX, Xue J, Lau WY, Wu MC, Cheng SQ: Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus. Ann Surg Oncol 2010;17:2073–2080.

12 Lam CM, Lo CM, Yuen WK, Liu CL, Fan ST, Poon RT: Prolonged survival in selected patients following surgical resection for pulmonary metastasis from hepatocellular carcinoma. Br J Surg 1998;85:1190–1200.

13 Chen F, Sato K, Fujinaga T, Sonobe M, Shoji T, Sakai H, Miyahara R, Bando T, Okubo K, Hirata T, Date H: Pulmonary resection for metastases from hepatocellular carcinoma. World J Surg 2008;32:2213–2217.

14 Kitano K, Murayama T, Sakamoto M, Nagayama K, Ueno K, Murakawa T, Nakajima J: Outcome and survival analysis of pulmonary metastasectomy for hepatocellular carcinoma. Eur J Cardiothorac Surg 2012;41:376–382.

15 Sano T, Izuiishi K, Takebayashi R, Akamoto S, Kakinoki K, Okano K, Masaki T, Suzuki Y: Surgical approach for extrahepatic metastasis of HCC in the abdominal cavity. Hepatogastroenterology 2011;58:2067–2070.

16 Liu CL, Fan ST, Poon RT, Wong J: Hepatic resection for bilobar hepatocellular carcinoma: is it justified? Arch Surg 2003;3:100–104.

17 Choi D, Lim HK, Jou WJ, Kim SJ, Kim MJ, Rhim H, Kim YS, Yoo BC, Paik SW, Park CK: Combined hepatectomy and radiofrequency ablation for multifocal hepatocellular carcinomas: long-term follow-up results and prognostic factors. Ann Surg Oncol 2007;14:3510–3518.

18 Cheung TT, Ng KK, Chok KS, Chan SC, Poon RT, Lo CM, Fan ST: Combined resection and radiofrequency ablation for multifocal hepatocellular carcinoma: prognosis and outcomes. World J Gastroenterol 2010;16:3056–3062.

19 Abuhalim A, Limongelli P, Healey AJ, Damrah O, Tait P, Jackson J, Habib N, Jiao LR: Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg 2008;247:49–57.

20 Polignano FM, Quyn AJ, de Figueiredo RS, Henderson NA, Kulli C, Tait IS: Laparoscopic versus open liver segmentectomy: prospective, case-matched, intention-to-treat analysis of clinical outcomes and cost-effectiveness. Surg Endosc 2008;22:2564–2570.

21 Lai EC, Tang CN, Ha JP, Li MK: Laparoscopic liver resection for hepatocellular carcinoma: ten-year experience in a single center. Arch Surg 2009;144:143–147, discussion 148.

22 Lee KF, Chong CN, Wong J, Cheung YS, Wong J, Lai P: Long-term results of laparoscopic hepatectomy versus open hepatectomy for hepatocellular carcinoma: a case-matched analysis. World J Surg 2011;35:2260–2274.

23 Cheung TT, Poon RT, Yuen WK, Chok KS, Jenkins CR, Chan SC, Fan ST, Lo CM: Long-term survival analysis of pure laparoscopic versus open hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a single-center experience. Ann Surg 2013;257:506–511.

24 Liu CL, Fan ST, Cheung ST, Lo CM, Ng IO, Wong J: Anterior approach versus conventional approach right hepatic resection for large hepatocellular carcinoma: a prospective randomized controlled study. Ann Surg 2006;244:194–203.

25 Wu TJ, Wang F, Lin YS, Chan KM, Yu MC, Lee WC: Right hepatectomy by the anterior method with liver hanging versus conventional approach for large hepatocellular carcinomas. Br J Surg 2010;97:1070–1078.

26 Lo CM, Liu CL, Chan SC, Poon RT, Ng IO, Fan ST, Poon RT: A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 2007;245:831–842.

27 Takayama T, Sekine T, Makuuchi M, Yamazaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000;356:802–807.

28 Bayer and Onyx report phase III study results of Nexavar® (sorafenib) as adjuvant treatment for patients with liver cancer who have undergone surgery or local ablation [news release]. Available at: http://www.onyx.com/view.cfm/700/bayer-and-onyx-report-phase-3-study-results-of-nexavar-sorafenib-as-adjunctive-treatment-for-patients-with-liver-cancer-who-have-undergone-surgery-or-local-ablation. Accessed 5 May 2014.

29 Chan AC, Poon RT, Cheung TT, et al: Survival analysis of re-resection versus RFA for intrahepatic recurrence after hepatectomy for hepatocellular carcinoma. World J Surg 2011;36:151–156.

30 Chan AC, Chan SC, Chok KS, Cheung TT, Chiu DW, Poon RT, Fan ST, Lo CM: Treatment strategy for recurrent hepatocellular carcinoma: salvage transplantation, repeated resection, or radiofrequency ablation? Liver Transpl 2013;19:411–419.

31 Bismuth H, Majno PE, Adam R: Liver transplantation for hepatocellular carcinoma. Semin Liver Dis 1999;19:311–322.

32 Bigourdan JM, Jaeck D, Meyer N, Meyer C, Oussoultzoglou E, Bachellier P, Weber JC, Audeh M, Doffoel M, Wolf P: Small hepatocellular carcinoma in Child A cirrhotic patients: hepatic resection versus transplantation. Liver Transpl 2003;9:513–520.

33 Yao FY, Ferrell L, Bass NM, Watson JJ, Bachetti P, Venook A, Ascher NL, Roberts JP: Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394–1403.

34 Fernández JA, Robles R, Marin C, Sánchez-Bueno F, Ramirez P, Pons JA, Garre MC, Pérez D, Parrilla A, Navalón JC, Parrilla P: Can we expand the indications for liver transplantation among hepatocellular carcinoma patients with increased tumor size? Transplant Proc 2003;35:1818–1820.
35 Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM, Lipshutz G, Yersiz H, Lu DS, Lassman C, Tong MJ, Hiatt JR, Busuttil RW: Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007;246:502–509, discussion 509–511.

36 Patel SS, Arrington AK, McKenzie S, et al: Milan Criteria and UCSF Criteria: A preliminary comparative study of liver transplantation outcomes in the United States. Int J Hepatol 2012;2012:253517.

37 Soejima Y, Taketomi A, Yoshizumi T, Uchiyama H, Aishima S, Terashi T, Shimada M, Maehara Y: Extended indication for living donor liver transplantation in patients with hepatocellular carcinoma. Transplantation 2007;83:893–899.

38 Kwon CH, Kim DJ, Han YS, Park JB, Choi GS, Kim SJ, Joh JW, Lee SK: HCC in living donor liver transplantation: can we expand the Milan criteria? Dig Dis 2007;25:313–319.

39 Jonas S, Mittler J, Pascher A, Schumacher G, Thervath T, Benckert C, Rudolph B, Neuhaus P: Living donor liver transplantation of the right lobe for hepatocellular carcinoma in cirrhosis in a European center. Liver Transpl 2007;13:986–993.

40 Takada Y, Ito T, Ueda M, Sakamoto S, Haga H, Maetani Y, Ogawa K, Ogura F, Egawa H, Uemoto S: Liver cancer in living donor liver transplantation: findings from the A2ALL Retrospective Cohort Study. Am J Transplant 2012;12(Suppl 3):S170–S174.

41 Zheng SS, Xu X, Wu J, Chen J, Wang WL, Zhang M, Liang TB, Wu LM: Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation 2008;85:1762–1763.

42 Liang W, Wu L, Ling X, Schroder PM, Ju W, Wang D, Shang Y, Kong Y, Guo Z, He X: Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl 2012;18:1226–1236.

43 Sandhu L, Sandroussi C, Guha M, Selzner M, Ghanekar A, Cattral MS, McGilvray ID, Levy G, Greig PD, Renner EL, Grant DR: Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: comparable survival and recurrence. Liver Transpl 2012;18:315–322.

44 Trotter JF, Adam R, Lo CM, Kenison J: Documented deaths of hepatic lobe donors for living donor liver transplantation. Liver Transpl 2006;12:1485–1488.

45 Freise CE, Gillespie BW, Koffron AJ, Lok AS, Pruett TL, Emond JC, Fair JH, Fisher RA, Olthoff KM, Trotter JF, Ghobrial RM, Everhart JE, A2ALL Study Group: Recipient morbidity after living and deceased donor liver transplantation: findings from the A2ALL Retrospective Cohort Study. Am J Transplant 2008;8:2569–2579.

46 Belghiti J, Carr BJ, Greig PD, Lencioni R, Poon RT: Treatment before liver transplantation for HCC. Ann Surg Oncol 2008;15:993–1000.

47 Pompili M, Abbate V, Nicolardi E, et al: Bridge treatments for HCC in the waiting list for liver transplantation. Open Transpl J 2011;5:44–49.

48 Yao FY, Breitenstein S, Broelsch CE, Dufour JF, Sherman M: Does a patient qualify for liver transplantation after the down-staging of hepatocellular carcinoma? Liver Transpl 2011;17(Suppl 2):S109–S116.

49 Gordon-Weeks AN, Snaith A, Petrinic T, Friend PJ, Burls A, Silva MA: Systematic review of outcome of down-staging hepatocellular cancer before liver transplantation in patients outside the Milan criteria. Br J Surg 2011;98:1201–1208.

50 Lau WY, Leung TW, Yu SC, Ho SK: Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future. Ann Surg 2003;237:171–179.

51 Lam VW, Ng KK, Chok KS, et al: Risk factors and prognostic factors of local recurrence after RFA of hepatocellular carcinoma. J Am Coll Surg 2008;207:20–29.

52 N’Kontchou G, Mahamoudi A, Aout M, et al: RFA of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology 2009;50:1475–1483.

53 Lam VW, Ng KK, Chok KS, Cheung TT, Yuen J, Tung H, Tso WK, Fan ST, Poon RT: Incomplete ablation after radiofrequency ablation of hepatocellular carcinoma: analysis of risk factors and prognostic factors. Ann Surg Oncol 2008;15:782–790.

54 Poon RT, Ng KK, Lam CM, Ai Y, Yuen J, Fan ST: Effectiveness of radiofrequency ablation for hepatocellular carcinoma larger than 3 cm in diameter. Arch Surg 2004;139:281–287.

55 Lu Z, Wen F, Guo Q, Liang H, Mao X, Sun H: Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a meta-analysis of randomized-controlled trials. Eur J Gastroenterol Hepatol 2013;25:187–194.

56 Peng ZW, Chen MS, Liang HH, Gao HJ, Zhang YJ, Li IQ, Zhang YQ, Lau WY: A case-control study comparing percutaneous radiofrequency ablation alone or combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. Eur J Surg Oncol 2010;36:257–263.

57 Peng ZW, Zhang YJ, Chen MS, Xu L, Liang HH, Lin XJ, Guo RP, Zhang YQ, Lau WY: Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 2013;31:426–432.

58 Duan C, Liu M, Zhang Z, Ma K, Bie P: Radiofrequency ablation versus hepatic resection for the treatment of early-stage hepatocellular carcinoma meeting Milan criteria: a systematic review and meta-analysis. World J Surg Oncol 2013;11:90.

59 Chen MS, Li IQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, Lin XJ, Lau WY: A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006;243:321–328.

60 Lai EC, Tang CN: RFA versus hepatic resection for hepatocellular carcinoma within the Milan criteria – a comparative study. Int J Surg 2013;11:77–80.
61 Khan MR, Poon RT, Ng KK, et al: Surgical vs percutaneous RFA for hepatocellular carcinoma in dangerous locations. World J Gastroenterol 2011;17:123–129.

62 Khan MR, Poon RT, Ng KK, et al: Comparison of percutaneous and surgical approaches for RFA of small and medium hepatocellular carcinoma. Arch Surg 2007;142:1136–1143.

63 Orlando A, Leandro G, Olivo M, Andriulli A, Cottone M: Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 2009;104:514–524.

64 Xu HX, Xie XY, Lu MD, Chen JW, Yin XY, Xu ZF, Liu GJ: Ultrasound-guided percutaneous thermal ablation of hepatocellular carcinoma using microwave and radiofrequency ablation. Clin Radiol 2004;59:53–61.

65 Shibata T, Imuro Y, Yamamoto Y, Maetani Y, Ametani F, Itoh K, Konishi J: Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology 2002;223:331–337.

66 Dong B, Liang P, Yu X, Su L, Cheng Z, Zhang J: Percutaneous sonographically guided microwave coagulation therapy for hepatocellular carcinoma: results in 234 patients. AJR Am J Roentgenol 2003;180:1547–1555.

67 Lee KF, Hui JW, Cheung YS, Wong JS, Chong CN, Wong J, Lai PB: Surgical ablation of hepatocellular carcinoma with 2.45-GHz microwave: a critical appraisal of treatment outcomes. Hong Kong Med J 2012;18:85–91.

68 Goldberg SN, Charboneau JW, Dodd GD 3rd, Dupuy DE, Gervais DA, Gillams AR, Kane RA, Lee FT Jr, Livraghi T, McGahan JP, Rhim H, Silverman SG, Solbiati L, Vogl TJ, Wood BJ, International Working Group on Image-Guided Tumor Ablation: Image-guided tumor ablation: proposal for standardization of terms and reporting criteria. Radiology 2003;228:335–345.

69 Wright AS, Sampson LA, Warner TF, Mahvi DM, Lee FT Jr: Radiofrequency versus microwave ablation in a hepatic porcine model. Radiology 2005;236:132–139.

70 Bhardwaj N, Dormer J, Ahmad F, Strickland AD, Gravante G, West K, Dennison AR, Lloyd DM: Microwave ablation of the liver: a description of lesion evolution over time and an investigation of the heat sink effect. Pathology 2011;43:725–731.

71 Ng KK, Poon RT, Chan SC, Chok KS, Cheung TT, Tong H, Chu F, Tsos WK, Yu WC, Lo CM, Fan ST: High-intensity focused ultrasound for hepatocellular carcinoma: a single-center experience. Ann Surg 2011;253:981–987.

72 Cheung TT, Fan ST, Chu FS, Jenkins CR, Chok KS, Tsang SH, Dai WC, Chan AC, Chan SC, Poon RT, Lo CM: Survival analysis of high-intensity focused ultrasound ablation in patients with small hepatocellular carcinoma. HPB Oxf 2013;15:567–573.

73 Chan AC, Cheung TT, Fan ST, Chok KS, Chan SC, Poon RT, Lo CM: Survival analysis of high-intensity focused ultrasound therapy versus radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma. Ann Surg 2013;257:686–692.

74 Cheung TT, Chu FS, Jenkins CR, Tsang DS, Chok KS, Chan AC, Yau TC, Chan SC, Poon RT, Lo CM, Fan ST: Tolerance of high-intensity focused ultrasound ablation in patients with hepatocellular carcinoma. World J Surg 2012;36:2420–2427.

75 Cheung TT, Fan ST, Chok KS, Chan SC, Chok KS, Tsang SH, Dai WC, Poon RT, Lo CM: High-intensity focused ultrasound ablation: an effective bridging therapy for hepatocellular carcinoma patients. World J Gastroenterol 2013;19:3083–3089.

76 Kingham TP, Karkar AM, D’Angeli CA, Allen PJ, Dematteo RP, Getrajdman GI, Sofocleous CT, Solomon SB, Jarnagin WR, Fong Y: Ablation of perivascular hepatic malignant tumors with irreversible electroperforation. J Am Coll Surg 2012;215:379–387.

77 Cannon R, Ellis S, Hayes D, Narayan G, Martin RC 2nd: Safety and early efficacy of irreversible electroperforation for hepatic tumors in proximity to vital structures. J Surg Oncol 2013;107:544–549.

78 Cheung W, Kavanoudas H, Roberts S, Szakader B, Kemp W, Thomson KR: Irreversible electroperforation for unresectable hepatocellular carcinoma: initial experience and review of safety and outcomes. Technol Cancer Res Treat 2013;12:233–241.

79 Lo CM, Ngan H, Tsos WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164–1171.

80 Llovet JM, Real MI, Montañá X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J, Barcelona Liver Cancer Group: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734–1739.

81 Llovet JM, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37:429–442.

82 Georgiadis CS, Hong K, D’Angelo M, Geschwind JF: Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2005;16:1653–1659.

83 Chung GE, Lee JH, Kim HY, Hwang SY, Kim JS, Chung JW, Yoon JH, Lee HS, Kim YJ: Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 2011;258:627–634.

84 Luo J, Guo RP, Lai EC, Zhang YJ, Lau WY, Chen MS, Shi M: Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol 2011;18:413–420.
Xue TC, Xie XY, Zhang L, Yin X, Zhang BH, Ren ZG: Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis. BMC Gastroenterol 2013;13:60.

Graziani IW, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbaur K, Jaschke W, Margreiter R, Vogel W: Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003;9:557–563.

Boucharb-Portier A, Lapointe R, Perreault P, et al: Transcatheter arterial chemoembolization of hepatocellular carcinoma as a bridge to liver transplantation: a retrospective study. Int J Hepatol 2011;2011:974514.

Seehofer D, Nebrig M, Denecke T, Kroencke T, Weichert W, Stockmann M, Somasundaram R, Schott E, Puhl G, Neuhaus P: Impact of neoadjuvant transarterial chemoembolization on tumor recurrence and patient survival after liver transplantation for hepatocellular carcinoma: a retrospective analysis. Clin Transplant 2012;26:764–774.

Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Tibballs J, Meyer T, Patch DW, Burroughs AK: Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007;30:6–25.

Lammer I, Malagari K, Vogl T, Pilleul F, Denys A, Watkins A, Pitton M, Sergent G, Pfammatter T, Terraz S, Benhamou Y, Avajon Y, Gruenberger T, Pomoni M, Langenberger H, Schuchmann M, Dumortier J, Mueller C, Chevallier P, Lencioni R, PRECISION V Investigators: Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010;33:41–52.

Gao S, Yang Z, Zheng Z, Yao J, Deng M, Xie H, Zheng S, Zhou L: Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology 2013;60:813–820.

Ernst O, Sergent G, Mizrahi D, Delemazure O, Paris JC, L’Herminé C: Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization: comparison of planned periodic chemoembolization and chemoembolization based on tumor response. AJR Am J Roentgenol 1999;172:59–64.

Georgiades C, Geschwind JF, Harrison N, Hines-Peralta A, Liapi E, Hong K, Wu Z, Kamel I, Frangakis C: Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment? Radiology 2012;265:115–123.

Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, Lencioni R: Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011;37:212–220.

Park JW, Amarpurkar D, Chao Y, Chou PJ, Geschwind JF, Goh KL, Han KH, Kudo M, Lee HC, Lee RC, Lesmana LA, Lim HY, Pak SW, Poon RT, Tan CK, Tanwanndeet T, Teng G, Cheng AL: Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). Liver Int 2013;33:327–337.

Caturelli E, Siena DA, Fusilli S, Villani MR, Schiavone G, Nardella M, Balzano S, Florio F: Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of damage to nontumorous liver tissue – long-term prospective study. Radiology 2000;215:123–128.

Clark TW: Complications of hepatic chemoembolization. Semin Intervention Radiol 2006;23:119–125.

Zhao Y, Cai G, Zhou L, Liu L, Qi X, Bai M, Li Y, Fan D, Han G: Transarterial chemoembolization in hepatocellular carcinoma with vascular invasion or extrahepatic metastasis: A systematic review. Asia Pac J Clin Oncol 2013;9:357–364.

Hilgard P, Hamami M, Fouly AE, Scherag A, Müller S, Ertle J, Heusner T, Cicinnati VR, Paul A, Bockisch A, van der Brugge P, van Dijk AL, Lim HY, Paik SW, Poon RT, Tan CK, Tanwanndeet T, Teng G, Cheng AL: Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). Liver Int 2013;33:327–337.

Benhamou Y, Avajon Y, Gruenberger T, Pomoni M, Langenberger H, Schuchmann M, Dumortier J, Mueller C, Chevallier P, Lencioni R, PRECISION V Investigators: Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010;33:41–52.
Lau WY, Ho SK, Yu SC, Lai EC, Liew CT, Leung TW: Salvage surgery following downstaging of unresectable hepatocellular carcinoma. Ann Surg 2004;240:299–305.

Kulik LM, Atassi B, van Holsbeek L, Souman T, Lewandowski RJ, Mulcahy MF, Hunter RD, Nemcek AA Jr, Abecassis MM, Haines KG 3rd, Salem R: Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006;94:572–586.

Infarrrairaegui M, Pardo F, Bilbao JJ, Rotellar F, Benito A, D’Avola D, Herrero JJ, Rodriguez M, Martí P, Zozaya G, Domínguez I, Quirgo J, Sangro B: Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma. Eur J Surg Oncol 2012;38:594–601.

Kooby DA, Egnatashvili V, Srinivasan S, Chamsuddin A, Delman KA, Kauh J, Staley CA 3rd, Kim HS: Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2010;21:224–230.

Karr BJ, Kondragunta V, Buch SC, Branch RA: Therapeutic equivalence in survival for hepatic arterial chemotherapy and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 2010;116:1305–1314.

Kolligs FT, et al: SIRTACE: A randomized multicentre pilot trial of selective internal radioembolisation (SIRT) with yttrium-90 microspheres versus transarterial chemoembolisation (TACE) in patients with unresectable hepatocellular carcinoma (HCC). J Hepatol 2012;56:Suppl 1:S61–S66.

Clinical Trials.gov. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (HCC) (TRACE). Available at: http://clinicaltrials.gov/show/NCT01381211. Accessed 25 October 2013.

Fuss M, Salter BJ, Herman TS, Thomas CR Jr: External beam radiation therapy for hepatocellular carcinoma: potential of intensity-modulated and image-guided radiation therapy. Gastroenterology 2004;127(Suppl 1):S206–S217.

Mornex F, Girard N, Beziat C, Kubas A, Khodri M, Trepo C, Merle P: Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies – mature results of the French Phase II RTF-1 trial. Int J Radiat Oncol Biol Phys 2006;66:1152–1158.

Chan LC, Chiu SK, Chan SL: Stereotactic radiotherapy for hepatocellular carcinoma: report of a local single-centre experience. Hong Kong Med J 2011;17:112–118.

Law AL, Ng WT, Lee MC, Chan AT, Fung KH, Li P, Lao WC, Lee AW: Treatment of primary liver cancer using highly-conformal radiotherapy with kV-image guidance and respiratory control. Radiother Oncol 2012;102:56–61.

Seong J, Park HC, Han KH, Chon CY: Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: a retrospective study of 158 patients. Int J Radiat Oncol Biol Phys 2003;55:329–336.

Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RK, Dinniwell RE, Kassam T, Rangash J, Cummings B, Sykes J, Sherman M, Knox JJ, Dawson LA: Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 2013;31:1631–1639.

Honda Y, Kimura T, Aikata H, Kobayashi T, Fukuhara T, Masaki K, Nakahara T, Naeshiro N, Ono A, Miyaki D, Nagaoki Y, Kawaoka T, Takaki S, Hiramatsu A, Ishikawa M, Kakizawa H, Kenjo M, Takahashi S, Awai K, Nagata Y, Chayama K: Stereotactic body radiotherapy combined with transarterial arterial chemoembolization for small hepatocellular carcinoma. J Gastroenterol Hepatol 2013;28:530–536.

Xu LT, Zhou ZH, Lin JH, Chen Z, Wang K, Wang P, Zhu XY, Shen YH, Meng QZ, Liu LM: Clinical study of transcatheter arterial chemoembolization combined with 3-dimensional conformal radiotherapy for hepatocellular carcinoma. Eur J Surg Oncol 2011;37:245–251.

Yoon SM, Lim YS, Won HJ, Kim JH, Kim KM, Lee HC, Chung YH, Lee YS, Lee SG, Park JH, Suh DJ: Radiotherapy plus transcatheter chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. Int J Radiat Oncol Biol Phys 2012;82:2004–2011.

Tang QH, Li AJ, Yang GM, Lai EC, Zhou WP, Jiang ZH, Lau WY, Wu MC: Surgical resection versus conformal radiotherapy combined with TACE for resectable hepatocellular carcinoma with portal vein tumor thrombus: a comparative study. World J Surg 2013;37:1362–1370.

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, de Oliveira AC, Santoro A, Raoul JL, Forner A, LLoyd P, Di Bisceglie AM, Asian-Pacific Working Party on Hepatocellular Carcinoma: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–390.

Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25–34.

Chiu J, Tang YF, Yao TJ, Wong A, Wong H, Leung R, Chan P, Cheung TT, Chan AC, Pang R, Fan ST, Poon R, Yau T: The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits. Cancer 2012;118:5293–5301.
127 Pressiani T, Boni C, Rimassa L, Labianca R, Fagioli S, Salvagni S, Ferrari D, Cortesi E, Porta C, Mucciariini C, Latini L, Carnaghi C, Banzì M, Fanello S, De Giorgio M, Lutman FR, Torzilli G, Tommasini MA, Ceriani R, Covini G, Tronconi MC, Giordano L, Locopo N, Naimo S, Santoro A: Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. Ann Oncol 2013;24:406–411.

128 Kim JE, Ryu BY, Ryu MH, Chang HM, Suh DJ, Lee HC, Lim YS, Kim KM, Kang YK: Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. Cancer Chemother Pharmacol 2011;68:1285–1290.

129 Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, Ladrón de Güevara L, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Cihon F, Heldner S, Marrero JA: First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib) non-interventional study. Int J Clin Pract 2012;66:675–683.

130 Sherman M, Mazzaferro V, Amadori D, et al.: Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma and vascular invasion or extrahepatic spread: A subanalysis from the SHARP trial. J Clin Oncol 2008;26(Suppl): abstract 4584.

131 Chong YH, Han G, Yoon JH, Yang J, Wang J, Shao GL, Kim BI, Lee TY, Chao Y: Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial. Int J Cancer 2013;132:2448–2458.

132 Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, Yoon JH, Horii T, Kumada H, Hayashi N, Kaneko S, Tsusbuchi H, Suh DJ, Furuse J, Okusaka T, Tanaka K, Matsui O, Wada M, Yamaguchi I, Ohya T, Meinhardt G, Okita K: Phase III study of sorafenib plus doxorubicin-oemolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011;47:2117–2127.

133 Sansonno D, Lauletta G, Russi S, Conteduca V, Sansonno L, Dammacco F: Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. Oncologist 2012;17:359–366.

134 Lencioni R, Llovet JM, Han G, et al.: Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial. J Clin Oncol 2012;30(4 Suppl):abstract LBA154.

135 Abou-Alfa GK, Johnson P, Knox JJ, Capano M, Davidenko I, Lacava J, Leung T, Gansukh B, Saltz LB: Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010;304:2154–2160.

136 Yau T, Cheung FY, Lee FA, et al.: A multicenter phase II study of sorafenib, capecitabine, and oxaliplatin (SEC)OX in patients with advanced hepatocellular carcinoma: Final results of Hong Kong-Singapore Hepatocellular Carcinoma Research Collaborative Group study. J Clin Oncol 2011;33:31(Suppl).

137 Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, Lu HW, Leung JM, Lai JW, Lo AO, Chan HY, Wong VW: Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013;58:1537–1547.

138 Hosaka T, Suzuki K, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H: Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013;58:98–107.

139 Singal AK, Salameh H, Kuo YF, Fontana RJ: Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther 2010;31:98–106.

140 Wong JS, Wong GL, Tsoi KK, Wong VW, Cheung SY, Chong CN, Wong J, Lee KE, Lai PB, Chan HL: Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther 2011;33:1104–1112.

141 Liaw YF, Kao JH, Piratvisuth T, et al.: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012;6:164–187.

142 Miyake Y, Takaki A, Iwasaki Y, Yamamoto K: Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatocellular carcinoma: Phase II, randomized, double-blind placebo (HCC): Phase II, randomized, double-blind placebo (HCC). J Clin Oncol 2008;26(Suppl): abstract LBA145.

143 Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ: Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878–1887.

144 Lao XM, Luo G, Ye LT, Luo C, Shi M, Wang D, Guo R, Chen M, Li S, Lin X, Yuan Y: Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma. Liver Int 2013;33:595–604.

145 Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ: Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878–1887.

146 European Association for the Study of the Liver European Organisation For Research And Treatment Of Cancer: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908–943.

147 Bruix J, Sherman M American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020–1022.

148 Bruix J, Sherman M Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology 2005;42:1208–1236.